Merkel cell carcinoma of the head and neck: a single institutional experience by Morand, G et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Merkel cell carcinoma of the head and neck: a single institutional experience
Morand, G; Vital, D; Pézier, T; Holzmann, D; Roessle, M; Cozzio, A; Huber, G F
Abstract: Merkel cell carcinoma (MCC) is a rare cutaneous malignancy occurring mostly in older im-
munocompromized Caucasian males. A growing incidence of MCC has been reported in epidemiological
studies. Treatment of MCC usually consists of surgical excision, pathological lymph node evaluation, and
adjuvant radiotherapy. This paper reports the experience of a single tertiary center institution with 17
head and neck Merkel cell carcinoma patients. Median followup for the cohort was 37.5 months. After
five years, recurrence-free survival, disease specific survival, and overall survival were 85%, 90%, and
83%, respectively. Our limited data support the use of adjuvant radiotherapy. We also report two cases
of MCC located at the vestibule of the nose and two cases of spontaneous regression after diagnostic
biopsy. About 40% of our patients were referred to our center for surgical revision and pathological
lymph node evaluation. Increased awareness of MCC and an interdisciplinary approach are essential in
the management of MCC.
DOI: 10.1155/2013/325086
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-76334
Published Version
Originally published at:
Morand, G; Vital, D; Pézier, T; Holzmann, D; Roessle, M; Cozzio, A; Huber, G F (2013). Merkel cell
carcinoma of the head and neck: a single institutional experience. Journal of Skin Cancer, 2013:325086.
DOI: 10.1155/2013/325086
Hindawi Publishing Corporation
Journal of Skin Cancer
Volume 2013, Article ID 325086, 7 pages
http://dx.doi.org/10.1155/2013/325086
Research Article
Merkel Cell Carcinoma of the Head and Neck:
A Single Institutional Experience
G.Morand,1 D. Vital,1 T. Pézier,1 D. Holzmann,1 M. Roessle,2 A. Cozzio,3 and G. F. Huber1
1 Division of Otolaryngology, Head and Neck Surgery, University Hospital Zurich, Frauenklinikstraße 24, 8091 Zurich, Switzerland
2 Institute of Surgical Pathology, University Hospital Zurich, Frauenklinikstraße 24, 8091 Zurich, Switzerland
3Division of Dermatology, University Hospital Zurich, Frauenklinikstraße 24, 8091 Zurich, Switzerland
Correspondence should be addressed to G. Morand; gregoire.morand@usz.ch
Received 28 October 2012; Accepted 22 December 2012
Academic Editor: Boban M. Erovic
Copyright © 2013 G. Morand et al. is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Merkel cell carcinoma (MCC) is a rare cutaneousmalignancy occurringmostly in older immunocompromized Caucasianmales. A
growing incidence of MCC has been reported in epidemiological studies. Treatment of MCC usually consists of surgical excision,
pathological lymph node evaluation, and adjuvant radiotherapy. is paper reports the experience of a single tertiary center
institution with 17 head and neck Merkel cell carcinoma patients. Median followup for the cohort was 37.5 months. Aer �ve
years, recurrence-free survival, disease speci�c survival, and overall survival were 85%, 90%, and 83%, respectively. Our limited
data support the use of adjuvant radiotherapy. We also report two cases of MCC located at the vestibule of the nose and two cases
of spontaneous regression aer diagnostic biopsy. About 40% of our patients were referred to our center for surgical revision
and pathological lymph node evaluation. Increased awareness of MCC and an interdisciplinary approach are essential in the
management of MCC.
1. Introduction
In 1875, Merkel, professor of anatomy at the University of
Rostock, Germany, for the �rst time described “Tastzellen”
(touch cells)—later known as Merkel cells—in the epidermis
of domestic animals and humans [1]. In 1972, Toker �rst
reported a case series of �ve patients with “trabecular carci-
noma” and recognized a “distinct pathological entity,” with a
“capricious clinical behaviour” [2]. It took Tang and Toker
another six years to determine that trabecular carcinoma
“most probably” derives fromMerkel cells [3].
More recently, in 2008, a previously unknown poly-
omavirus was found to be integrated inMerkel cell carcinoma
(MCC) [4].Nowknown asMerkel Cell polyomavirus (MCV),
this virus is indeed thought to be a causative agent inMCC [5,
6] and has been associated with about 80% of MCC cases [4,
7–10]. A previous study from our institution reported similar
prevalence of MCV inMCC [11]. Con�icting evidence exists
about the prognostic value of MCV status [7, 8, 12–14].
Important diﬀerential diagnoses of MCC are basal cell
carcinoma, small cell melanoma, lymphoma, small blue
round cell tumours, and especially metastatic small cell
lung carcinoma [15]. A thorough histo- or cytopathological
workup including immunohistochemistry (e.g., CK20, TTF-
1, and neuroendocrine markers) [16] combined with entire
examination and clinical history usually allows to diﬀerenti-
ate the above mentioned entities.
A recent study by Smith et al. [17] drawn from an US-
population based database (SEER) with over 4,300 MCC
patients showed that 48% of all MCC are primarily located in
the head and neck area (HN-MCC), with men representing
about 61% of the patient population. e overwhelming
majority of patients were Caucasian.
Hodgson [18] reported a incidence of Merkel cell carci-
noma of 0.44/100,000/year in 2001 from the same database.
Interestingly, there seems to be a sharp increase in the num-
ber of cases being reported. Hodgson performed a com-
parative analysis and showed an 8% estimated annual per-
centage change (EAPC) in MCC incidence from 1986 until
2001. is change was attributed to the ageing of popula-
tion and the growing prevalence of immunocompromized
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patients, two known risk factors for MCC [18–22]. Further-
more, the authors noted that this change might also result
from increased awareness and reporting of MCC [18]. A
further risk factor for MCC is UVB exposure, as shown in
epidemiological studies [23] and mutations analysis of TP53
[24]. Expression of p53 has been correlated to MCV-negative
MCC [13, 14, 25], thus suggesting a diﬀerent pathogenesis in
MCV-positive and MCV-negative MCC.
e authors of another epidemiological study from e
Netherlands [19] reported similar incidence trends of MCC
with an EAPC of 8%. For the same period, the EAPC for
melanoma and squamous cell carcinoma of the skin were 4%
and about 2%, respectively.
e prognosis of MCC remains poor, with a 5-year
relative survival for local, regional, and metastatic disease
of about 75%, 50%, and 20%, respectively [19]. Smith et
al. reported a 5-year disease speci�c survival for pN0, pN1,
and M1 in HN-MCC patients of 83.3%, 58.3%, and 31.3%,
respectively [17]. Epidemiological analyses have established
several prognostic factors in HN-MCC [17]: male sex, >T2-
primaries, N-positive, M-positive, and tumour location at
the lip were shown to be independent negative risk factors.
Unlike for nonhead andneck-MCC (NHN-MCC), increasing
tumour size was not a prognostic factor for HN-MCC [17].
Lemos et al. have shown the critical impact of patho-
logical lymph node evaluation for MCC patients [26]. For
example, in the management of cutaneous melanoma, sen-
tinel lymph node biopsy (SLNB) is now a standard of
care [27]. Analogically, SLNB has gained popularity in the
past years in the management of MCC, currently being
recommended as standard treatment [28], independently of
the size of the primary tumour [29–32], as SLNB permits
a pathological lymph node evaluation with less morbidity
compared to elective neck dissection [33, 34]. SLNB studies
have shown that about 30% of cN0 MCC patients harbour
occult metastasis [35, 36], with up to 20% false negative rate
[37, 38].
Prophylactic irradiation is usually accepted as an alterna-
tive in the management of the clinically negative neck [39].
e superiority of adjuvant radiotherapy in local and
regional control has been shown in a meta-analysis of obser-
vational studies [40]. A recent multicentric prospective ran-
domized controlled trial conducted in France again showed
improved locoregional control [41]. Both studies could not
prove a signi�cant advantage of adjuvant radiotherapy on
disease speci�c survival.
For inoperable patients, an in-�eld control rate of 75%
has been reported with radiotherapy alone, with 55Gy as a
minimum dose for macroscopic disease [42]. Other studies
also show acceptable results for radiotherapy alone [43, 44].
e aim of this study was to report the experience of a
single institution tertiary center in Switzerland.
2. Methods
Aer local ethics committee approval, we performed a
retrospective chart review of all patients treated for a Merkel
cell carcinoma in the department for Otorhinolaryngol-
ogy—Head and Neck Surgery—at the University Hospital
of Zurich, Switzerland, between January 1990 and August
2012. We searched our electronic patient database using the
following keywords: “Merkel cell carcinoma,” “Merkel cell,”
and the ICD-10-Code for Merkel cell carcinoma (C44.∗). A
single reviewer (GM) was responsible for sorting the eligible
patients out of the generated list.
Inclusion criteria were con�rmed histopathological diag-
nosis of Merkel cell carcinoma and location of the primary
tumour in the head and neck. Only patients treated at
our department were included. Patients treated by other
departments (e.g., plastic surgery) were not included.
For each patient, the following parameters were assessed:
tumour site, age, sex, immunosuppression, TNM-stadium
(AJCC, 7th Edition 2010 [39]), treatment modality of local
and regional disease, location of primary tumour, surgical
margins, recurrence-free survival (�FS), disease speci�c sur-
vival (DSS), and overall survival (OS).
Descriptive statistics were performed using Microso
Excel 2007. Kaplan Meier estimates were calculated using
IBM SPSS 19 and the survival functions were compared by
log rank tests.
3. Results
3.1. Demographics, Tumour Location, Staging, and Risk Fac-
tors. Seventeen patients (4 male, 13 female, ratio 1 : 3.3) met
the inclusion criteria (Table 1). e mean age was 71 y (SD
15.8, median 73, range 40–89). Ten primaries (58%) were
located on the cheek, two on the external ear (12%), two
in the vestibule of the nose (12%), one at the lower lip
(6%), one at the eyelid (6%), and one at the glabella (6%).
Diabetes was reported for one patient (6%); HIV/AIDS or
immunosuppression aer organ transplant was not reported
for any patients.
According to AJCC, 7th Edition 2010 [45], stage Ia was
present in four cases (24%); stage Ib in one (6%); stage IIa
in two (12%); stage IIb in two (12%); stages IIc and IIIa in
zero; stage IIIb in four (24%); and stage IV in zero cases. In
four patients (24%), tumour stage was not available because
of missing data.
Median followup for the cohort was 37.5 months (mean
62, SD 72, range 5–288). One patient (6%) died of Merkel
cell carcinoma, three (18%) of other causes. Aer �ve
years, recurrence-free survival (�FS), disease speci�c survival
(DSS), and overall survival (OS) were 85%, 90%, and 83%,
respectively (Figure 1).
3.2. Treatment Options, Surgical Margins, Pathological Lymph
Node Evaluation. Sixteen patients (94%) underwent primary
surgical resection. One patient (6%) underwent primary
radiotherapy, as surgical excision would have resulted in
complete removal of the nose, which was unacceptable to the
patient. is patient was excluded from further analysis.
In three out of sixteen patients (19%), surgical excision
margins of 2 cm were reported and in two cases margins of
1 cm (13%). In one case (6%), Mohs surgery was used.
In three cases (19%), margins smaller than 1 cm were
used, twice because the surgeon did not considerMCC in the
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T 1: Summary of patients characteristics.
∘ Age Sex Location Side T N M erapy Recurrence Followup Outcome
1 73 f Cheek Right pT2 cN0 M0 Excision only No 170 MCC unrelated death
2 81 f Cheek Le pT2 pN0 (0/31) M0 Excision + ND + RT No 9 RFS
3 52 f Vestibule of nose Right pT1 pN0 (sn 0/4) M0 Excision + SLNB No 18 RFS
4 88 f Glabella Middle pT1 cN0 M0 Excision only Yes§ 27 disease speci�c death
5 86 f Pinna le pTx cN0 M0 Excision + RT∗ No 0 lost to followup
6 64 m Cheek Right pT1 pN0 (sn 0/1) M0 Excision + SLNB + RT No 72 RFS
7 57 f Cheek Right pT1 pN0 (sn 0/3) M0 Excision + SLNB No 66 RFS
8 73 f Lower lid Le pTx pN0 (sn 0/1) M0 Excision + SLNB Yes♮ 74 MCC unrelated death
9 86 m Cheek Le pT2 pN0 (0/23) M0 Excision + ND + RT∗∗ No 36 RFS
10 65 f Cheek Le pTx pN0 (sn 0/2) M0 Excision + SLNB + RT No 39 RFS
11 40 f Cheek Le pT1 pN1b (4/26) M0 Excision + ND + RT No 21 RFS
12 62 f Cheek Right pT1 pN0 (0/40) M0 Excision + ND + RT No 24 RFS
13 86 m Pinna Right pT1 pN2 (3/21) M0 Excision + ND + RT No 11 MCC unrelated death
14 51 f Cheek Right pTx cN0 M0 Excision + RT No 288 RFS
15 72 m Lower lip Middle pTx pN1b (3/28)$ M0 Excision + ND + RT No 63 RFS
16 77 f Cheek Right pT2 pN1b (1/25) M0 Excision + ND + RT No 72 RFS
17 89 f Vestibule of nose Le cT2 cN0 M0 Radiotherapy only No 5 RFS
Age in years; f: female; m: male. TNM stadium according to AJCC, 7th Edition, 2010. RT: radiotherapy. $bilateral neck dissection, le 3/14, right 0/14. ∗RT
refused by patient. ∗∗RT could not be performed because of wound healing problems. §regional recurrence aer 11 months. ♮local recurrence aer 12 months.
Followup in months. SLNB: sentinel lymph node biopsy. ND: neck dissection. RFS: recurrence-free survival. MCC: Merkel cell carcinoma.
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clinical diﬀerential diagnosis. For the remaining case, a two-
step surgery was chosen, with the use of arti�cial skin gra,
whilst a de�nitive histological margin was performed which
led to a further excision a week later.
In seven cases (44%), surgical margins were not available;
all these patients were referred to our institution aer having
primary surgery elsewhere.
All of the patients who had planned 2 cm excision
margins had clear histological margins. One of the two
patients with a planned 1 cmmargin had to undergo a second
operation to obtain clear histological margins. is patient
(number 8) did not receive adjuvant radiotherapy as the
primary was located at the lower lid and concerns were raised
about the irradiation of the eye. He suﬀered a local recurrence
one year later and had to undergo extended resection with
orbital exenteration, free �ap reconstruction, and adjuvant
radiotherapy.
Of the patients who were initially operated in other
hospitals and for those with planned excision margins of
<1 cm, nine out of ten (90%) had to undergo at least one
second surgical intervention. Data is incomplete for the last
patient.
ere was not statistical relation between surgical mar-
gins and recurrence-free survival (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃).
Of the sixteen patients who underwent primary surgical
excision, sentinel lymph node biopsy was performed in �ve
patients (31%) and was always negative. Mean number of
sentinel nodes was 2.2 (range 1–4).
Two patients (12%) underwent therapeutic selective neck
dissection for clinically positive neck disease (patients 11 and
13).
Five patients (31%) had elective selective neck dissections,
showing regional disease in two cases (12%).
Five patients (31%) underwent, in addition to neck
dissection, super�cial parotidectomy, due to the localisation
of the primary tumour and the expected lymphatic drainage.
No disease was found in any of the parotid specimens.
Five patients (31%) did not have any pathological node
evaluation, in one case because of the patient comorbidities.
is patient (number 4) went on to develop regional recur-
rence 11 months later. He could not undergo salvage neck
dissection and was treated with locoregional radiotherapy.
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A fewmonths later, he had distantmetastatic disease and died
twenty-six months aer the initial surgery.
3.3. Recurrence, Radiotherapy, and Outcome. Two patients
(12%) developed the locoregional recurrence. Patient 8 had a
primary at the lower eyelid with a local recurrence 12months
aer primary surgery. Patient 4 showed a regional recurrence,
as discussed above.ese patients received radiotherapy aer
locoregional recurrence.
In eleven patients (69%), adjuvant radiotherapy was
recommended. One patient (6%) refused and another patient
could not undergo radiotherapy because of severe wound
healing problems.
ree patients (31%) did not have any radiation. Two
of them underwent excision biopsy outside our clinic and
were referred for revision surgery and pathological node
evaluation. For both patients, the revision specimens and
SLNB were free of tumour in the histopathological analysis.
Adjuvant radiotherapy was therefore not performed.
Of the nine patients who had adjuvant radiotherapy fol-
lowing surgery, none suﬀered recurrence. Without adjuvant
radiotherapy following surgery, two of six patients (33%)
developed locoregional recurrence. ere was a trend to a
better RFS in patients who underwent adjuvant radiation
(𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃, log rank test).
Mean adjuvant radiation dose was 62.4Gy (SD 4.8,
median 62, range 54–70).
4. Discussion
MCC is a raremalignancy, occurringmostly in older immun-
ocompromized Caucasian males. As the population in most
Western countries continues ageing [46] and the prevalence
of immunosuppression increases [47], epidemiological stud-
ies have shown an increase in MCC incidence.
e growing incidence of MCC has led to an increased
awareness and reporting of MCC. Searching for “Merkel cell
carcinoma” in PubMed database reveals a steady increase in
results by year, with about 40 publications per year in the 90s,
to over 160 publications for the year 2010 or 2011.
We report here a single institution retrospective analysis.
e demographics of our patient cohort diﬀer from other
retrospective reports, as do our survival rates [17, 48–
51]. e mean age is slightly lower than in other larger
reports [17] and we have a predominance of women and no
immunosuppressed patients, which could be explained by
our relatively small patient cohort.
Considering a cohort with elderly patients, a diﬀerence
between the OS and the DSS can be explained by comorbidi-
ties. We had in fact more disease unrelated deaths as disease
speci�c deaths in the follow-up period.
In comparison to other reports [26, 40, 52], our
favourable DSS and DFS could be explained by high rate
of combined therapy, high rate of pathological lymph node
dissection, low rate of distant disease at diagnosis, a pre-
dominance of women [17], and lack of immunosuppressed
patients [22]. Our results must however been interpreted in
light of the small cohort size.
As reported elsewhere [53], we did not �nd surgical
margins to signi�cantly aﬀect recurrence-free survival. is
is consistent with the fact that clear histological margins were
obtained for every patient, independently of the surgical exci-
sion margins chosen initially. For HN-MCC, we recommend
margins of 1 cm, or nonfeasible, two-step or Mohs surgery
[28, 54, 55].
We observed a trend supporting the use of adjuvant
radiotherapy. Although not signi�cant, this result complies
with stronger evidence [40, 41].
We report two cases of MCC occurring in the vestibule
of the nose. is location has been reported very rarely
in the literature [56]. One patient was treated using Mohs
surgery. For the other patient, primary radiotherapy was
chosen because an ablation of the nose would have been
necessary to obtain clear surgical margins.
We also report two cases of surgical revision aer external
excision biopsy with lack of MCC cells in the revision
specimen and SLNB, thus who either had been fully excised
surgically or with spontaneous regression following biopsy,
as already described in many other reports [56–61].
Analogically, MCC of unknown primary has also been
described [62, 63]. Although the mechanism of regression
is not known, immune in�ltration has been proposed [64].
However, in a recent study with 37 patients, no signi�cant
increase in intratumoral CD8 T-cell in�ltration aer biopsy
could be found [65].
As seven out of seventeen of the patients (41%) in this
study were referred to surgical revision and pathological
lymph node evaluation, we think that continuing education
is essential, particularly for house physicians and general
practitioners, who need to be aware of this rare but increasing
malignancy, usually gentle in presentation [66, 67].
Our results should be interpreted cautiously, as biased by
missing data and heterogeneous population. Our statistical
analysis lacks power due to our low number of patientS
and events. As a tertiary center, we also suﬀer referral bias.
Nevertheless, bearing these caveats in mind, we believe that a
few lessons can be learned from this paper.
In conclusion, we believe that increased awareness of
MCC is essential to ensure an optimal initial management.
Failure to do so can lead to a higher number of surgical inter-
ventions and missing or incomplete pathological staging.
Surgical removal of HN-MCC should assure oncological
suﬃcient treatment, while preserving cosmetic or functional
essential structure. An alternate surgical technique should be
used, as appropriate.
To overcome these challenges, we strongly believe that a
multidisciplinary approach and collaboration is essential. In
accordance with the available literature, in Zurich, we have
established an internal guideline, with a systematic assessing
of several variables, thus allowing high quality data for further
studies.
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